期刊
FUTURE CARDIOLOGY
卷 1, 期 1, 页码 39-59出版社
FUTURE MEDICINE LTD
DOI: 10.1517/14796678.1.1.39
关键词
adipose autodysharmonia; adiposopathy diabetes; Food and Drug Administration; hypertension; obesity metabolic cycle; metabolic syndrome; obesity; regulatory
资金
- Alteon
- Aventis
- Bayer
- Boehringer Ingelheim
- Boehringer Mannheim
- Bristol-Myers Squibb
- Fujisawa
- Ciba-Geigy
- GelTex
- Glaxo
- Genetech
- Hoechst Roussel
- KOS
- Lederle
- Marion Merrell Dow
- Merck
- Merck Schering-Plough
- Miles
- Novartis
- Parke-Davis
- Pfizer
- Purdue
- Reliant
- Roche
- Rorer
- Regeneron
- Sandoz
- Sankyo
- Sanofi
- Shering Plough
- Searle
- SmithKline Beacham
- Takeda
- TAP
- UpJohn
- Upsher Smith
- Warner-Lambert
- Wyeth-Ayerst
- AstraZenca
- NIH [K23-RR16075]
- NIH/DHS/DHHS [MO1-RR-00633]
- CDC [H75/CCH523202]
- AHA [0465017Y]
Adiposopathy is defined as pathological adipose tissue function that may be promoted and exacerbated by fat accumulation (adiposity) and sedentary lifestyle in genetically susceptible patients. Adiposopathy is a root cause of some of the most common metabolic diseases observed in clinical practice, including Type 2 diabetes mellitus, hypertension and dyslipidemia. The most common term for the metabolic consequences of adiposopathy is currently 'the metabolic syndrome'. Drug usage to treat the metabolic syndrome has focused on the safety and efficacy of treatments directed towards individual components of the metabolic syndrome, and not so much upon adiposopathy itself. However, enough is known about the pathophysiology of adiposopathy to propose diagnostic criteria. Regulatory issues are important obstacles to the research and development of new drug treatments for the metabolic syndrome. It is hoped that these obstacles can, to some extent, be addressed and overcome by clearly defining and increasing our understanding of adiposopathy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据